In the above article [De Clerq E (2001) J Pharmacol Exp Ther297:1–10], the structure that pertains to neplanocin A and 3-deazaneplanocin in Fig. 2 was presented incorrectly. The corrected figure follows. The author regrets any confusion or inconvenience caused by this error.
Figure 2
Prototype (representative) antiviral agents. Polyanionic substances: PVAS and PVS. Receptor antagonists: bicyclam AMD3100. NRTIs: stavudine (d4T). NNRTIs: emivirine (MKC 442). Nucleoside analogs: valaciclovir and brivudin. Acyclic nucleoside phosphonates: cidofovir, adefovir, and tenofovir. IMP dehydrogenase inhibitors: EICAR and mycophenolic acid. SAH hydrolase inhibitors: neplanocin A derivatives.
- The American Society for Pharmacology and Experimental Therapeutics